Abstract
Adhesions are a major cause of small bowel obstruction, posing significant challenges in diagnosis, treatment and prevention. Adhesive small bowel obstruction has a substantial impact on morbidity and imposes a considerable socioeconomic burden. Therefore, it is of interest to study the therapeutic use of oral gastrografin in treating acute adhesive small bowel obstruction. Acute small bowel obstruction (SBO), accounting for 6-30% of cases. Adhesions are responsible for approximately 65-75% of SBO cases, necessitating careful assessment and management. This study, conducted at Chirayu Medical College & Hospital, Bhopal, India from June 2021 to May 2022, included 87 patients with 94 episodes of adhesive SBO. Initial conservative treatment resolved 63 episodes (67.02%) within 48 hours. The remaining 31 episodes (32.98%) were subjected to a Gastrografin challenge, where 23 cases (74.2%) showed successful dye transit to the colon within 24 hours, while 8 cases (25.8%) required surgical intervention. The findings suggest the Oral Gastrografin represents a significant advancement in the conservative management of acute adhesive small bowel obstruction, offering a non-invasive, effective and safe alternative to surgery for many patients. Its integration into clinical practice can enhance patient care and improve clinical outcomes in the management of ASBO.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call